GSK PLC DRNGSK PLC DRNGSK PLC DRN

GSK PLC DRN

No trades
See on Supercharts

Key facts today

GSK plc reported Q3 2024 revenue of $10.42 billion, a 2% decline from Q3 2023. Core EPS increased 5% to $1.29. The company raised its full-year guidance, anticipating 12%-13% revenue growth.
The U.S. FDA revoked the emergency use authorization for GSK's sotrovimab due to its expired shelf life and lack of patient administration approval for over a year.
Analyze the impactAnalyze the impact
Market capitalization
‪423.71 B‬BRL
4.504BRL
‪30.50 B‬BRL
‪187.69 B‬BRL
‪3.73 B‬
Beta (1Y)
0.03

About GSK PLC ORD GBP0.3125


CEO
Emma N. Walmsley
Headquarters
London
Website
ISIN
BRG1SKBDR008
FIGI
BBG00XX9K400
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
G
17RI
GLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45
Yield to maturity
6.06%
Maturity date
Dec 18, 2045
G
XS217060907
GLAXOSM.CAP. MTN 20/35MTN
Yield to maturity
6.04%
Maturity date
May 12, 2035
G
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.91%
Maturity date
Mar 18, 2043
G
83GI
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042
Yield to maturity
5.58%
Maturity date
Apr 10, 2042
G
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
5.30%
Maturity date
May 15, 2038
G
71ZC
GLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39
Yield to maturity
5.20%
Maturity date
Mar 9, 2039
G
GSK4632357
GlaxoSmithKline Capital, Inc. 3.625% 15-MAY-2025
Yield to maturity
5.11%
Maturity date
May 15, 2025
G
US377373AH8
GLAXOSM.CAP. 19/29
Yield to maturity
4.95%
Maturity date
Jun 1, 2029
G
US377372AN7
GLAXOSMITHKLINE CAP.18/28
Yield to maturity
4.80%
Maturity date
May 15, 2028
G
AG99
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033
Yield to maturity
4.71%
Maturity date
Dec 19, 2033
G
XS217060184
GLAXOSM.CAP. MTN 20/28MTN
Yield to maturity
4.65%
Maturity date
Oct 12, 2028

Explore more bonds 

Curated watchlists where G1SK34 is featured.